What is [18F]fluoropropyl-trimethoprim ([18F]F-TMP) studying for bacterial infections?

This study is assessing how a radioactive imaging agent called [18F]F-TMP behaves in the body to detect bacterial infections. Researchers aim to understand its distribution and uptake in infected tissues using PET/CT scans. The University of Pennsylvania sponsors this research to improve infection imaging techniques.

Who may be eligible for this bacterial infection clinical trial?

Adults 18 years or older with known or suspected bacterial infections can be eligible. Both men and women may participate, but those who have used trimethoprim antibiotic recently or are pregnant or breastfeeding are excluded. Please review eligibility criteria for more details.

Is there any cost to participate in this bacterial infection clinical trial?

Study-related care, including the imaging agent and all trial visits, is provided at no cost. However, personal travel expenses and other costs may vary and are not guaranteed to be covered.

Actively Recruiting

Phase 1

Age: 18Years +

All Genders

ID04263792

PETCT Imaging Using 18FFluoropropyl-Trimethoprim to Study Distribution and Movement in Adults with Bacterial Infections

Led by University of Pennsylvania · Updated on 2026-02-05

Participants Needed

Research Sites

26 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating a radioactive tracer called 18Ffluoropropyl-trimethoprim 18FF-TMP, an imaging drug injected to detect active bacterial infections in the body using Positron Emission TomographyComputed Tomography PETCT. This Phase 1 study aims to understand how this tracer distributes and moves through the body in human patients with known or suspected bacterial infections. The tracer is based on trimethoprim, a widely used antibiotic, and is studied here for its imaging potential rather than treatment. Participants will join one of two study groups the Biodistribution cohort or the Dynamic cohort. The Biodistribution group, including up to 5 patients, will undergo several PETCT scans from head to mid-thigh or feet over about 4 hours to observe tracer distribution. The Dynamic group, with up to 15 patients, will have approximately 60 minutes of dynamic scanning followed by up to two static scans after injection of 18FF-TMP. These scans help researchers analyze tracer uptake and movement in the body over time. During the study, participants will have PETCT imaging sessions to monitor the tracers uptake in infected and non-infected tissues. Researchers will measure the tracers biodistribution and kinetics, including changes after therapy. Safety monitoring includes assessments for any inability to tolerate imaging and pregnancy testing for women of childbearing potential. The study duration for outcome measures is approximately 3 years, with no mention of long-term treatment or follow-up beyond imaging evaluations.

CONDITIONS

Brief Title

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

At least 18 years of age
Known or suspected bacterial infection confirmed by clinical documentation such as lab or pathology results, physician notes, or infection symptoms
Able to understand the study and provide written informed consent according to guidelines

You will not qualify if you...

Antibiotic treatment with trimethoprim within 48 hours before the baseline PET/CT scan
Unable to tolerate imaging procedures as assessed by study staff or physician
Having unstable or severe medical or psychological conditions that could affect safety or participation
Pregnant or breastfeeding; women of childbearing potential must have a negative urine pregnancy test before tracer injection

Research Team

Erin Schubert

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here